OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC
Edyta Maria Urbanska, Morten Grauslund, Peter R. Koffeldt, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13077-13077
Open Access | Times Cited: 6
Edyta Maria Urbanska, Morten Grauslund, Peter R. Koffeldt, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13077-13077
Open Access | Times Cited: 6
Showing 6 citing articles:
Therapeutic insights into epidermal growth factor receptor/reactive oxygen species proto-oncogene 1-receptor co-mutated non-small cell lung cancer: Crizotinib as a promising option
Yan Zhou, Botao Xu, Haiying Zhou, et al.
World Journal of Clinical Oncology (2025) Vol. 16, Iss. 3
Closed Access
Yan Zhou, Botao Xu, Haiying Zhou, et al.
World Journal of Clinical Oncology (2025) Vol. 16, Iss. 3
Closed Access
Tepotinib plus an EGFR tyrosine kinase inhibitor in patients with EGFR-mutant MET-altered NSCLC: A case series
Xiuning Le, Anna Eisert, Te‐Chun Hsia, et al.
Clinical Lung Cancer (2025)
Closed Access
Xiuning Le, Anna Eisert, Te‐Chun Hsia, et al.
Clinical Lung Cancer (2025)
Closed Access
Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer
Donatella Romaniello, Alessandra Morselli, Ilaria Marrocco
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 2957-2957
Open Access
Donatella Romaniello, Alessandra Morselli, Ilaria Marrocco
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 2957-2957
Open Access
MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis
Defeng Hu, Yixuan Hu, Shipeng Lei, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Defeng Hu, Yixuan Hu, Shipeng Lei, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Strategies Beyond 3rd EGFR‐TKI Acquired Resistance: Opportunities and Challenges
Xiangmei Zhou, Liang Zeng, Zhe Huang, et al.
Cancer Medicine (2025) Vol. 14, Iss. 9
Open Access
Xiangmei Zhou, Liang Zeng, Zhe Huang, et al.
Cancer Medicine (2025) Vol. 14, Iss. 9
Open Access
MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations
Jan Trøst Jørgensen, Edyta Maria Urbanska, Jens Mollerup
Translational Lung Cancer Research (2024) Vol. 13, Iss. 4, pp. 940-946
Open Access | Times Cited: 2
Jan Trøst Jørgensen, Edyta Maria Urbanska, Jens Mollerup
Translational Lung Cancer Research (2024) Vol. 13, Iss. 4, pp. 940-946
Open Access | Times Cited: 2
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy
Veronique de Jager, Peter J. A. M. PLOMP, Marthe S. Paats, et al.
ESMO Open (2024) Vol. 9, Iss. 11, pp. 103966-103966
Open Access | Times Cited: 1
Veronique de Jager, Peter J. A. M. PLOMP, Marthe S. Paats, et al.
ESMO Open (2024) Vol. 9, Iss. 11, pp. 103966-103966
Open Access | Times Cited: 1
